Since 1999, the Employer Health Benefits Survey has documented trends in employer-sponsored health insurance. Every year, private and non-federal public employers with three or more employees complete the survey.
Trends in ICHRA adoption, product innovation, and regulatory developments signal that this benefits model isn’t just here to stay — it’s poised to help redefine how we think about employer-sponsored healthcare. The post 2025 Outlook: Significant Investments in ICHRA Signal Changes Ahead appeared first on MedCity News.
TURLOCK, California — California, al igual que gran parte del país, no está formando a suficientes enfermeras para satisfacer las necesidades de una población envejecida y diversa. Esto genera una escasez de personal que podría poner en peligro la calidad de la atención a los pacientes. Según datos estatales, casi el 60% de los condados…
Innovative approaches to home care will only be successful if organizations can ensure the safety of the professionals who enter patient homes. To do that, they’ll need to embrace new technologies that support in-home caregivers in real-time, and implement new protocols that ensure they are provided with the security and comfort they deserve. The post…
Recent updates to the HIPAA Security Rule shift from addressable to mandatory requirements
IKS Health acquired healthcare AI startup ARAI to strengthen the technology underpinning its automation tools, as well as reduce its dependence on third-party AI models. The post IKS Health Acquires ARAI to Build Out Specialized AI Stack appeared first on MedCity News.
The question is no longer whether healthcare innovation is accelerating. The question is where investors gain access to generate the strongest returns. The post Healthcare’s Next Source of Alpha Is Moving Upstream appeared first on MedCity News.
Approval of Syndax’s Revuforj for acute leukemia makes the twice-daily pill the first in a new class of drugs that block a cancer-driving protein called menin. Other companies developing menin inhibitors include Kura Oncology, Biomea Fusion, and Johnson & Johnson subsidiary Janssen. The post Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval appeared first…
Presidential candidate Trump claims credit for SCOTUS’ Dobbs decision and says that as a result, the “states are voting.” States are making decisions on abortion policy, but it’s mostly been state legislatures, not voters. Few states with abortion bans have a process for citizen-initiated constitutional amendments. In those states, lawmakers and anti-abortion activists have attempted…
Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration. The biotech’s Series B round will finance clinical tests of two programs, each addressing a different stage of the disease….